Polysaccharide Derivatives for Sustained-Release Dosage Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sustained release pharmaceutical dosage forms using hydroxypropyl methylcellulose ether particles suffer from poor flowability, leading to variability in tablet weight and hardness, and low bulk density, which complicates manufacturing and blending processes.
Innovation Solution
Polysaccharide derivatives with a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and controlled particle distributions, including fine, fibrous, and spherical particles, are used to improve flowability and bulk density, enabling efficient blending and compression into uniform dosage forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If hydroxypropyl methylcellulose ether particles with very small size (at least 90% pass through 100 mesh screen) are used to achieve long release profile, then the release duration is improved, but the flowability deteriorates
Solution Approach 1:
The patent applies parameter changes by carefully controlling the particle size distribution parameters of the polysaccharide derivative. Specifically, it limits fine particles (LEFI < 40 μm) to ≤40 vol% and fibrous particles to ≤40 vol%, with their sum ≤50 vol%. This parameter control optimizes both flowability and sustained release performance, resolving the contradiction between small particle size (for long release) and poor flowability.
2Duration of action of moving object
If hydroxypropyl methylcellulose ether particles with very small size are used to achieve long release profile, then the release duration is improved, but the manufacturing precision deteriorates
Solution Approach 1:
The patent controls the particle size distribution parameters to limit fine and fibrous particles, which directly improves manufacturing precision. By constraining the volume percentages of problematic particle types, the invention reduces tablet weight variability and ensures more consistent dosing while maintaining the sustained release effect.
3Duration of action of moving object
If hydroxypropyl methylcellulose ether particles with very small size are used to achieve long release profile, then the release duration is improved, but the device complexity increases
Solution Approach 1:
By optimizing the particle size distribution parameters (limiting fine and fibrous particles), the patent improves flowability which reduces consolidation issues in processing equipment. This parameter control simplifies the manufacturing process and reduces equipment complexity while maintaining the long release profile.
4Ease of operation
If polysaccharide derivatives with small particle size (median EQPC < 140 micrometers) are used to improve flowability, then the flowability is improved, but the bulk density decreases
Solution Approach 1:
The patent applies parameter changes by controlling not only the median particle size (EQPC < 140 μm) but also the distribution parameters (fine particles ≤40 vol%, fibrous particles ≤40 vol%). This multi-parameter control achieves an optimal balance between flowability and bulk density, allowing efficient processing while maintaining reasonable packing density.
Data Source
Figure 1
Figure 2
AI summary
Polysaccharide derivatives having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both are useful for preparing dosage forms, particularly for preparing compressed sustained-release dosage forms: A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40 and an outlet diameter of about 50 mm, or B. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.